Bristol-Myers Squibb
Bristol -Myers Squibb, commonly abbreviated BMS, is a pharmaceutical company that was founded in 1989 by the merger of Bristol- Myers Squibb Company and Corporation. The company is headquartered in New York and is led by Lamberto Andreotti. In 2013 BMS generated a worldwide annual sales income of 16.4 billion USD ( 2013).
BMS is conducted on the Forbes Global 2000 list.
Products
BMS manufacturing facilities provide medicines and health products used in various therapy areas. To the company BMS belonged until recently, its subsidiary Mead Johnson, the diet products such as Enfamil baby formulas and vitamin supplements for children, such as Tri -Vi - Sol manufactures. Also at BMS were until recently the company Medical Imaging (until 2007), ConvaTec ostomy and wound care (until 2008). BMS also holds shares in ImClone, a biotech company. Originally BMS wanted the company ImClone completely take over. In August 2008, BMS was confronted with the launch of Clopidogrelbesilat the generic company Ratiopharm and Hexal in Germany, the Iscover with the world's second largest turnover by significantly lower prices made as a drug competition.
Among other things, BMS distributes patented drugs following:
- Orencia ( abatacept )
- Eliquis ( apixaban )
- Sprycel ( dasatinib )
- Yervoy ( ipilimumab )
- Baraclude ( entecavir )
- Reyataz (atazanavir )
- Sustiva (efavirenz )
- Videx ( didanosine )
- Zerit ( stavudine )
Criticism
The authors of the Black Markenfirmen throw the Group "Financing unethical drug trials, disability of a developing country in the manufacture and marketing of essential drugs and dubious practices in the elimination of competition " before.